BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21446013)

  • 1. FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.
    Kobayashi M; Huang Y; Jin C; Luo Y; Okamoto T; Wang F; McKeehan WL
    Prostate; 2011 Nov; 71(15):1691-700. PubMed ID: 21446013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
    Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
    Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.
    Hu R; Isaacs WB; Luo J
    Prostate; 2011 Nov; 71(15):1656-67. PubMed ID: 21446008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
    Kim SH; Singh SV
    Mol Cancer Ther; 2009 Jul; 8(7):1946-54. PubMed ID: 19584240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.
    Ito S; Ueda T; Ueno A; Nakagawa H; Taniguchi H; Hongo F; Kamoi K; Okihara K; Kawauchi A; Miki T
    FEBS J; 2014 Oct; 281(19):4506-18. PubMed ID: 25132193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
    He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
    Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D3 action in androgen receptor regulation and prostate cancer.
    Olshavsky NA; Groh EM; Comstock CE; Morey LM; Wang Y; Revelo MP; Burd C; Meller J; Knudsen KE
    Oncogene; 2008 May; 27(22):3111-21. PubMed ID: 18084330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
    Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
    Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
    Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
    Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA; Spencer-Dene B; Gamble SC; Waxman J; Bevan CL
    Endocr Relat Cancer; 2009 Dec; 16(4):1157-69. PubMed ID: 19635783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
    Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ
    Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
    Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
    Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
    Schiewer MJ; Morey LM; Burd CJ; Liu Y; Merry DE; Ho SM; Knudsen KE
    Oncogene; 2009 Feb; 28(7):1016-27. PubMed ID: 19079343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.